A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)

Summary

This study will evaluate thrice weekly dosing with vintafolide to find the maximum tolerable dose. The primary study hypothesis is that administration of vintafolide to participants with advanced solid tumors will have acceptable safety and tolerability.

Timeline

Start

2014-02

Primary completion

2014-05

Completion

2014-05

Drugs

Indications